The bad news: both government and business investment in R&D are falling. The good news: Canada’s research output and reputation are stellar. How long can that last?
LAVAL, Que. | Actelion Pharmaceuticals Canada has announced that a pivotal study with macitentan in patients with pulmonary arterial hypertension (PAH) has demonstrated a significant reduction in morbidity and mortality.